Compare BR & WAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BR | WAT |
|---|---|---|
| Founded | 1962 | 1958 |
| Country | United States | United States |
| Employees | N/A | 7900 |
| Industry | Business Services | Biotechnology: Laboratory Analytical Instruments |
| Sector | Consumer Discretionary | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.1B | 29.3B |
| IPO Year | 2006 | 1996 |
| Metric | BR | WAT |
|---|---|---|
| Price | $171.35 | $304.11 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 17 |
| Target Price | $246.17 | ★ $386.38 |
| AVG Volume (30 Days) | ★ 1.1M | 1.0M |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.24% | N/A |
| EPS Growth | ★ 21.16 | 0.47 |
| EPS | 3.82 | ★ 10.76 |
| Revenue | ★ $4,142,600,000.00 | $3,165,286,000.00 |
| Revenue This Year | $10.03 | $104.66 |
| Revenue Next Year | $4.46 | $10.53 |
| P/E Ratio | $45.91 | ★ $27.89 |
| Revenue Growth | N/A | ★ 6.99 |
| 52 Week Low | $163.71 | $275.05 |
| 52 Week High | $271.91 | $414.15 |
| Indicator | BR | WAT |
|---|---|---|
| Relative Strength Index (RSI) | 33.73 | 42.74 |
| Support Level | $163.71 | $281.62 |
| Resistance Level | $229.53 | $308.14 |
| Average True Range (ATR) | 5.27 | 8.35 |
| MACD | -0.65 | 2.54 |
| Stochastic Oscillator | 5.27 | 52.67 |
Broadridge Financial Solutions, which was spun off from Automatic Data Processing in 2007, is a leading provider of investor communication and technology-driven solutions to banks, broker/dealers, traditional and alternative-asset managers, wealth managers, and corporate issuers. Broadridge is composed of two operating segments: investor communication solutions and global technology and operations.
Waters sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. In early 2026, Waters merged with BD's life science and diagnostics business, which increased its concentration in diagnostics (versus none now) and discovery-related life science tools.